Bio & Healthcare Archives | Page 8 of 14 | Be Korea-savvy

Archive by category Bio & Healthcare

Celltrion’s New Autoimmune Disease Treatment Wins FDA Approval

Celltrion’s New Autoimmune Disease Treatment Wins FDA Approval

SEOUL, Oct. 23 (Korea Bizwire) — South Korea’s major pharmaceutical firm Celltrion Inc. said Monday its new autoimmune disease treatment has won approval from the U.S. Food and Drug Administration (FDA). The FDA approved Celltrion’s Zymfentra, a subcutaneous injection formulation of its infliximab Remsima, for maintenance therapy in adults with moderately to severely active ulcerative [...]

Shareholders of Both Celltrion, Celltrion Healthcare Approve Merger Plan

Shareholders of Both Celltrion, Celltrion Healthcare Approve Merger Plan

SEOUL, Oct. 23 (Korea Bizwire) — Shareholders of pharmaceutical firm Celltrion Inc. on Monday approved a plan to merge with its sales and marketing affiliate Celltrion Healthcare Co., company officials said. Celltrion Healthcare’s merger with Celltrion was also approved by the affiliate’s shareholders earlier in the day. The approval came about three months after Celltrion [...]

South Korea Grants Emergency Approval for Moderna’s Enhanced Vaccine

South Korea Grants Emergency Approval for Moderna’s Enhanced Vaccine

SEOUL, Sept. 26 (Korea Bizwire) – South Korea’s health authorities said Tuesday they approved the emergency use of Moderna Inc.’s updated COVID-19 vaccine to target today’s most common strain. The approval of the vaccine that targets the XBB.1.5 subvariant came as health authorities have advised people to get free and updated COVID-19 vaccines from Oct. [...]

SK Chemicals Explores Sale of Pharmaceutical Business to Glenwood Private Equity

SK Chemicals Explores Sale of Pharmaceutical Business to Glenwood Private Equity

SEOUL, Sept. 21 (Korea Bizwire) —SK Chemicals is contemplating the potential sale of its pharmaceutical business to Glenwood Private Equity (PE), a private equity fund manager. In response to a disclosure request from the Korea Exchange regarding Glenwood PE’s proposed acquisition of SK Chemicals’ pharmaceutical business unit, SK Chemicals stated, “We are in the process [...]

Celltrion Completes License Deal with J&J to Sell Autoimmune Biosimilar in U.S. in 2025

Celltrion Completes License Deal with J&J to Sell Autoimmune Biosimilar in U.S. in 2025

SEOUL, Aug. 25 (Korea Bizwire) — South Korea’s major pharmaceutical firm Celltrion Inc. said Friday it has completed a license deal with Johnson & Johnson to sell its autoimmune disease treatment biosimilar in the United States. The deal will allow Celltrion’s CT-P43, the company’s ustekinumab biosimilar referencing Stelara, developed by J&J’s pharmaceutical unit of Janssen [...]

POSCO International Enters Animal Vaccine Export Market

POSCO International Enters Animal Vaccine Export Market

SEOUL, Aug. 25 (Korea Bizwire) — POSCO International Corp., the trading arm of South Korean steel giant POSCO Holdings Co., said Thursday it exported a swine pneumonia vaccine to National Veterinary Joint Stock Co. (NAVETCO), Vietnam’s premier animal vaccine enterprise, marking its maiden venture into the realm of animal vaccine exportation. This achievement is the [...]

SK bioscience Inks Deal with Australian Firm to Develop Patch-type Typhoid Vaccine

SK bioscience Inks Deal with Australian Firm to Develop Patch-type Typhoid Vaccine

SEOUL, Aug. 24 (Korea Bizwire) — SK bioscience Co. said Thursday it has reached a deal with Vaxxas, an Australian biotechnology company, to jointly develop a new patch-type typhoid vaccine. The global charitable foundation Wellcome will fund the collaboration for the first two years, awarding US$3.67 million to conduct the first-phase clinical trial, according to [...]

SK bioscience to Provide 5 mln Doses of Cell-based Flu Vaccine SKYCellflu

SK bioscience to Provide 5 mln Doses of Cell-based Flu Vaccine SKYCellflu

SEOUL, Aug. 23 (Korea Bizwire) — SK bioscience Co., a pharmaceutical affiliate under South Korea’s SK Group, said Wednesday it will produce 5 million doses of its signature cell-based influenza vaccine SKYCellflu nationwide from next month for the coming winter season. It resumed the production two years after it had stopped manufacturing the prefilled syringe-typed [...]